Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Goldenbiotech LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, TCHERKASSKAYA, OLGA V, and is situated in 1 distinct art unit. The 1 pending action represents the entirety of the company's current active prosecution at the USPTO. This profile shows a targeted approach to securing intellectual property in the biotech sector, with a minimal administrative footprint.
The busiest examiner, TCHERKASSKAYA, OLGA V, is handling the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the administrative requirements for this portfolio are low. This centralized structure allows the legal team to focus exclusively on the examination style and procedural preferences of a single individual. Practitioners should carefully manage the 1 pending office action by analyzing the specific requirements of TCHERKASSKAYA, OLGA V to ensure a successful outcome for this focused portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18978365 | Self-Retaining Implantable Drug Delivery Device | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18978365 | Self-Retaining Implantable Drug Delivery Device | TCHERKASSKAYA, OLGA V | 1615 | §103DP | Non-Final OA | — | Pending | Dec 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGoldenbiotech LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga V Tcherkasskaya has the most, with 1 of Goldenbiotech LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
